Skip to main content
TECX
NASDAQ Life Sciences

Tectonic 10-Q: $21.3M Q3 Loss, $234.7M Cash, $22.3M Net ATM Proceeds

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$19.42
Mkt Cap
$379.649M
52W Low
$15.52
52W High
$39.528
52W Position info
25% above low
Off High info
51% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

TECX sits 25% above its 52-week low of $15.52.

Summary

Tectonic's Q3 10-Q confirms the $21.3M quarterly loss and $234.7M cash position reported in today's 8-K, and details $22.3M of net ATM proceeds from 660,492 shares sold in the quarter at a $34.45 average.


Key Events · Earnings and Guidance · TECX

  • Q3 Loss Widens on Higher R&D

    Net loss was $21.3 million versus $19.0 million a year earlier; R&D rose to $17.4 million from $16.9 million and G&A to $6.0 million from $5.0 million.

  • ATM Sold $22.3M Net in Q3

    660,492 shares sold at a $34.45 average for $22.7 million gross and $22.3 million net; year-to-date 1,092,798 shares for $35.4 million net, leaving $63.9 million available on the $100 million program.

  • Cash Runway Past APEX Readout

    Cash and equivalents of $234.7 million at September 30, 2026, with management stating resources fund operations beyond twelve months from issuance and no going-concern doubt.

  • APEX Phase 2 Data Due January 2027

    Enrollment of 191 patients completed June 2026 and the IDMC recommended continuation in July 2026; topline TX45 results in PH-HFpEF are expected by end of January 2027.


Analysis · TECX · Life Sciences

The headline numbers match this morning's 8-K, but the 10-Q is where the capital structure actually gets quantified. Tectonic sold 660,492 shares under its ATM in Q3 at a $34.45 average, raising $22.3M net, and has now sold 1,092,798 shares for $35.4M net year-to-date. That is real dilution already executed, not a shelf authorization — share count rose to 19,935,375 from 18,738,249 at year-end. Against that, $234.7M of cash with no going-concern language and a stated runway beyond twelve months means the company is funded well past the January 2027 APEX Phase 2 readout, which is the event that will actually reprice the stock.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TECX was trading at $19.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $379.6M. The 52-week trading range was $15.52 to $39.53. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TECX - Latest Insights

TECX
Nov 05, 2026, 4:28 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.42
Real-time Price: $22.44 info
Change: +$3.02 (+16%) info
Market Cap: $413.523M info
TECX
Sep 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $23.51
Real-time Price: $22.44 info
Change: -$1.07 (-5%) info
Market Cap: $413.523M info
TECX
Aug 31, 2026, 10:29 AM EDT
Source: Coinpedia
Importance Score:
7
Price at Filing: $30.88
Real-time Price: $22.44 info
Change: -$8.44 (-27%) info
Market Cap: $413.523M info
TECX
Aug 30, 2026, 2:40 PM EDT
Source: The Block
Importance Score:
9
Price at Filing: $35.62
Real-time Price: $22.44 info
Change: -$13.18 (-37%) info
Market Cap: $413.523M info
TECX
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.22
Real-time Price: $22.44 info
Change: -$7.78 (-26%) info
Market Cap: $413.523M info